Gan & Lee Pharmaceuticals.

This large, late-stage study aims to see if a new injectable drug called GZR18 works as well or better than the established medication Wegovy (semaglutide) for weight management. It will involve 420 adults who are overweight or have obesity, with or without type 2 diabetes. Parti…

This early-stage study is testing an experimental injection called GZR18 in people who are overweight or obese. The main goals are to see how the injection affects how quickly the stomach empties and whether it changes how the body processes three common medications (digoxin, ros…

This study is testing a new injectable diabetes drug, GZR4, against a once-weekly insulin. It aims to see which one better controls blood sugar levels, is safer, and affects weight in people with type 2 diabetes who are already using insulin. About 300 adults will participate to …

This study is for people who have already completed a year-long trial of the GZR18 weight loss injection. It aims to see if continuing the treatment with injections every four weeks (instead of every two) for another 24 weeks is safe and effective at helping people maintain or fu…

This study aims to understand how the experimental injection GZR18 is processed by the body in people with different levels of kidney function compared to those with normal kidneys. Researchers will give a single dose to 32 adults with and without kidney impairment and closely mo…

This study aims to check if a new manufacturing process for the GZR18 injection results in the same drug levels in the body as the old process. It will involve 138 healthy adult men who will receive a single dose. Researchers will measure the drug in the blood over 35 days and mo…